WHITE PAPER

A manufacturing platform for engineered neural tissue

Engineered neural tissues with long-projecting axons hold the potential to repair nerve injury and restore function after paralysis, yet their translation depends on manufacturing that produces them at defined, reproducible specifications. This brief describes Syntherian's controlled manufacturing and functional-qualification platform, the application programs it enables, and the scientific foundation on which it rests.

SEPTEMBER 2026 WHITE PAPER

Controlled manufacturing for engineered neural tissue.

  1. A manufacturing and functional-qualification platform that integrates cell sourcing, tissue assembly, long-axon growth, process control, and release testing.

  2. Defined sensory and motor neural tissues produced at reproducible specifications, with function measured before use.

  3. Application programs extending from research testbeds and partner-developed products to spinal cord reconstruction and living electrode interfaces.

  4. A scientific foundation drawn from peer-reviewed work of the Burrell and Cullen laboratories at the University of Pennsylvania.

VIEW THE WHITE PAPER

CLINICAL IMPACT

Advancing the next generation of medicine.

By resolving manufacturing and reproducibility constraints, Syntherian can accelerate engineered tissue technologies from preclinical validation toward clinical development, enable standardized production at meaningful scale, broaden patient access, and support cutting-edge regenerative therapies designed to restore function, transform outcomes, and change lives.